menu search

CUE / Cue Biopharma, Inc. (CUE) Soars 8.3%: Is Further Upside Left in the Stock?

Cue Biopharma, Inc. (CUE) Soars 8.3%: Is Further Upside Left in the Stock?
Cue Biopharma, Inc. (CUE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. Read More
Posted: Jan 27 2022, 06:55
Author Name: Zacks Investment Research
Views: 080337

CUE News  

Cue Biopharma, Inc. (CUE) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 9, 2023

Cue Biopharma, Inc. (CUE) Q2 2023 Earnings Call Transcript

Cue Biopharma, Inc. (NASDAQ:CUE ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Dan Passeri - Chief Executive Office more_horizontal

Cue Biopharma, Inc. (CUE) Q4 2022 Earnings Call Transcript

By Seeking Alpha
March 21, 2023

Cue Biopharma, Inc. (CUE) Q4 2022 Earnings Call Transcript

Cue Biopharma, Inc. (NASDAQ:CUE ) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Dan Passeri - CEO Matteo Levisetti - more_horizontal

Cue Biopharma, Inc. (CUE) Q3 2022 Earnings Call Transcript

By Seeking Alpha
November 14, 2022

Cue Biopharma, Inc. (CUE) Q3 2022 Earnings Call Transcript

Cue Biopharma, Inc. (NASDAQ:CUE ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Dan Passeri - Chief Executive Off more_horizontal

Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q2 2022 Results - Earnings Call Transcript

By Seeking Alpha
August 23, 2022

Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q2 2022 Results - Earnings Call Transcript

Cue Biopharma, Inc. (NASDAQ:CUE ) Q2 2022 Earnings Conference Call August 23, 2022 4:30 PM ET Company Participants Dan Passeri - Chief Executive Offic more_horizontal

Cue Biopharma, Inc. (CUE) Soars 8.3%: Is Further Upside Left in the Stock?

By Zacks Investment Research
January 27, 2022

Cue Biopharma, Inc. (CUE) Soars 8.3%: Is Further Upside Left in the Stock?

Cue Biopharma, Inc. (CUE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might no more_horizontal

Cue Biopharma, Inc. (CUE) Soars 8.3%: Is Further Upside Left in the Stock?

By Zacks Investment Research
January 27, 2022

Cue Biopharma, Inc. (CUE) Soars 8.3%: Is Further Upside Left in the Stock?

Cue Biopharma, Inc. (CUE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might no more_horizontal

Cue Biopharma, Inc. (CUE) Soars 8.3%: Is Further Upside Left in the Stock?

By Zacks Investment Research
January 27, 2022

Cue Biopharma, Inc. (CUE) Soars 8.3%: Is Further Upside Left in the Stock?

Cue Biopharma, Inc. (CUE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might no more_horizontal


Search within

Pages Search Results: